ABI-010 + ABI-007

ABI-010 + ABI-007 is a combination regimen consisting of ABI-010, an investigational agent, and ABI-007, an albumin-bound nanoparticle formulation of paclitaxel known as nab-paclitaxel. **ABI-007** (nab-paclitaxel) utilizes human serum albumin to deliver paclitaxel to tumors via endothelial receptors (such as gp60 and SPARC), enhancing intratumoral drug delivery and avoiding toxicities of solvent-based paclitaxel[1][2]. Mechanistically, ABI-007 inhibits microtubule disassembly resulting in mitotic arrest, cell cycle disruption, and apoptosis. **ABI-010** is less well-defined, but by established naming convention it is an investigational drug combined with ABI-007 in clinical studies. The combination modality suggests a dual-agent antineoplastic strategy, typical in oncology trials for synergistic cytotoxic effects. This combination has been investigated in advanced malignancies, though most published studies focus on ABI-007 plus other standard chemotherapeutics[1][4].

Other names

nab-paclitaxel + ABI-010